Strategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014

Natalia J Torok, Jonathan A. Dranoff, Detlef Schuppan, Scott L. Friedman

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

There is an urgent need to develop antifibrotic therapies for chronic liver disease, and clarify which endpoints in antifibrotic trials will be acceptable to regulatory agencies. The American Association for the Study of Liver Diseases sponsored an endpoints conference to help accelerate the efficient testing of antifibrotic agents and develop recommendations on clinical trial design for liver fibrosis. In this review, we summarize the salient and novel elements of this conference and provide directions for future clinical trial design. The article follows the structure of the conference and is organized into five areas: (1) antifibrotic trial design; (2) preclinical proof-of-concept studies; (3) pharmacological targets, including rationale and lessons to learn; (4) rational drug design and development; and (5) consensus and recommendations on design of clinical trials in liver fibrosis. Expert overviews and collaborative discussions helped to summarize the key unmet needs and directions for the future, including: (1) greater clarification of at-risk populations and study groups; (2) standardization of all elements of drug discovery and testing; (3) standardization of clinical trial approaches; (4) accelerated development of improved noninvasive markers; and (5) need for exploration of potential off-target toxicities of future antifibrotic drugs.

Original languageEnglish (US)
Pages (from-to)627-634
Number of pages8
JournalHepatology
Volume62
Issue number2
DOIs
StatePublished - Aug 1 2015

Fingerprint

Clinical Trials
Liver Cirrhosis
Pharmaceutical Preparations
Drug Design
Drug Discovery
Population Groups
Liver Diseases
Chronic Disease
Pharmacology
Direction compound
Therapeutics

ASJC Scopus subject areas

  • Hepatology

Cite this

Strategies and endpoints of antifibrotic drug trials : Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014. / Torok, Natalia J; Dranoff, Jonathan A.; Schuppan, Detlef; Friedman, Scott L.

In: Hepatology, Vol. 62, No. 2, 01.08.2015, p. 627-634.

Research output: Contribution to journalArticle

@article{d40ab57dd29449e0880dd2b0259bcf9a,
title = "Strategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014",
abstract = "There is an urgent need to develop antifibrotic therapies for chronic liver disease, and clarify which endpoints in antifibrotic trials will be acceptable to regulatory agencies. The American Association for the Study of Liver Diseases sponsored an endpoints conference to help accelerate the efficient testing of antifibrotic agents and develop recommendations on clinical trial design for liver fibrosis. In this review, we summarize the salient and novel elements of this conference and provide directions for future clinical trial design. The article follows the structure of the conference and is organized into five areas: (1) antifibrotic trial design; (2) preclinical proof-of-concept studies; (3) pharmacological targets, including rationale and lessons to learn; (4) rational drug design and development; and (5) consensus and recommendations on design of clinical trials in liver fibrosis. Expert overviews and collaborative discussions helped to summarize the key unmet needs and directions for the future, including: (1) greater clarification of at-risk populations and study groups; (2) standardization of all elements of drug discovery and testing; (3) standardization of clinical trial approaches; (4) accelerated development of improved noninvasive markers; and (5) need for exploration of potential off-target toxicities of future antifibrotic drugs.",
author = "Torok, {Natalia J} and Dranoff, {Jonathan A.} and Detlef Schuppan and Friedman, {Scott L.}",
year = "2015",
month = "8",
day = "1",
doi = "10.1002/hep.27720",
language = "English (US)",
volume = "62",
pages = "627--634",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

TY - JOUR

T1 - Strategies and endpoints of antifibrotic drug trials

T2 - Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014

AU - Torok, Natalia J

AU - Dranoff, Jonathan A.

AU - Schuppan, Detlef

AU - Friedman, Scott L.

PY - 2015/8/1

Y1 - 2015/8/1

N2 - There is an urgent need to develop antifibrotic therapies for chronic liver disease, and clarify which endpoints in antifibrotic trials will be acceptable to regulatory agencies. The American Association for the Study of Liver Diseases sponsored an endpoints conference to help accelerate the efficient testing of antifibrotic agents and develop recommendations on clinical trial design for liver fibrosis. In this review, we summarize the salient and novel elements of this conference and provide directions for future clinical trial design. The article follows the structure of the conference and is organized into five areas: (1) antifibrotic trial design; (2) preclinical proof-of-concept studies; (3) pharmacological targets, including rationale and lessons to learn; (4) rational drug design and development; and (5) consensus and recommendations on design of clinical trials in liver fibrosis. Expert overviews and collaborative discussions helped to summarize the key unmet needs and directions for the future, including: (1) greater clarification of at-risk populations and study groups; (2) standardization of all elements of drug discovery and testing; (3) standardization of clinical trial approaches; (4) accelerated development of improved noninvasive markers; and (5) need for exploration of potential off-target toxicities of future antifibrotic drugs.

AB - There is an urgent need to develop antifibrotic therapies for chronic liver disease, and clarify which endpoints in antifibrotic trials will be acceptable to regulatory agencies. The American Association for the Study of Liver Diseases sponsored an endpoints conference to help accelerate the efficient testing of antifibrotic agents and develop recommendations on clinical trial design for liver fibrosis. In this review, we summarize the salient and novel elements of this conference and provide directions for future clinical trial design. The article follows the structure of the conference and is organized into five areas: (1) antifibrotic trial design; (2) preclinical proof-of-concept studies; (3) pharmacological targets, including rationale and lessons to learn; (4) rational drug design and development; and (5) consensus and recommendations on design of clinical trials in liver fibrosis. Expert overviews and collaborative discussions helped to summarize the key unmet needs and directions for the future, including: (1) greater clarification of at-risk populations and study groups; (2) standardization of all elements of drug discovery and testing; (3) standardization of clinical trial approaches; (4) accelerated development of improved noninvasive markers; and (5) need for exploration of potential off-target toxicities of future antifibrotic drugs.

UR - http://www.scopus.com/inward/record.url?scp=84938212681&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938212681&partnerID=8YFLogxK

U2 - 10.1002/hep.27720

DO - 10.1002/hep.27720

M3 - Article

C2 - 25626988

AN - SCOPUS:84938212681

VL - 62

SP - 627

EP - 634

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 2

ER -